Information Provided By: 
Fly News Breaks for March 20, 2017
ARRY
Mar 20, 2017 | 07:26 EDT
JPMorgan analyst Anupam Rama says Array BioPharma's withdrawal of its new drug application filing for binimetinib in NRAS melanoma is a surprise. The analyst lowered his price target for the shares to $9 from $10 and thinks the stock today could be down 5%-10%. The analyst notes that NRAS melanoma only contributed around $100M in peak sales and $1 per share to his model. Rama keeps a Neutral rating on Array. The stock in premarket trading is down 14%, or $1.41, to $9.15.
News For ARRY From the Last 2 Days
ARRY
Apr 24, 2024 | 11:02 EDT
Wells Fargo notes that a group of seven domestic solar product makers, including First Solar (FSLR), filed a petition to levy anti-dumping and countervailing duties on solar imports from Cambodia, Malaysia, Thailand and Vietnam, looking for duties ranging from 70.4% to 271.5%. The firm, which included the "important reminder" that "this is just a petition," says the uncertainty created by the petition is "incrementally positive" for First Solar and negative for Canadian Solar (CSIQ), Array Technologies (ARRY) and Nextracker (NXT).
